Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Oleg Karyakin, Jonathan Zalevsky(Nektar Therapeutics (United States)), Alexander Guminski(The University of Sydney), Aleksandr Vasiliev(Russian Railways), Stanley Dai(Nektar Therapeutics (United States)), Konstantin Penkov, Daniel J. George(Duke University), Robert Zielinski, Arif Hussain(Manipal Academy of Higher Education), Monika Joshi, Edward Uchio(University of California, Irvine), Brendan D. Curti(Providence Portland Medical Center), Sumanta K. Pal(City of Hope), Howard Gurney(Radboud University Nijmegen), William R. Clark(Cancer Research UK), Mehmet Asım Bilen(Emory Healthcare), Omkar Marathe, Evgeniy Kopyltsov, Pedro C. Barata(University Hospitals Seidman Cancer Center), Nikolay Kislov(GOUZ YaO "Solovyov NV Clinical Emergency Hospital"), Dmitry Nosov(Central Clinical Hospital), Oleg Gladkov(Chelyabinsk Regional Clinical Oncology Center), Igor Lifirenko(Kursk Regional Clinical Oncology Center), David Campbell, Richard Zuniga, Mary Tagliaferri(Nektar Therapeutics (United States)), William Tester(Thomas Jefferson University), Kamal Patel, Simon Fu(BC Cancer Agency), Lily Tang(Nektar Therapeutics (United States)), Maria Nirvana Formiga(AC Camargo Hospital), Neeraj Agarwal(University of Utah), Emily Franks, Seresh Nair, Nils Gunnar Skare(Hospital Erasto Gaertner), Anila Qureshi(Bristol-Myers Squibb (United States)), Vladimir Kheifets, Saba Radhi(Texas Tech University), Francis Parnis(Centre for Cancer Biology), Walter Hong(Bayer (United States)), Sergey Varlamov, Alexandr Vasiliev(Russian Railways), Janaki Sharma(Albert Einstein College of Medicine)
Cited by 26
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k